Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Atopic Dermatitis disease market through 2033.

GlobalData estimated that the atopic dermatitis market was $10.8 billion across the 68MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $26.2 billion, increasing at a compound annual growth rate (CAGR) of 9.3%. This strong growth will be fuelled by driven by the launch of seven late-stage pipeline agents in the 7MM, increase in treatment options for all age groups and severities, high diagnosed prevalence of atopic dermatitis and high treatment rates across all markets in the 7MM, and novel mechanisms of action anticipated to enter the atopic dermatitis market over the forecast period.

Scope

Overview of AD – including epidemiology, disease etiology and management.​

Annualized atopic dermatitis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, and Japan over the 10-year forecast period.​

Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.​

Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers and barriers.

Key Highlights

The AD market will exhibit significant growth between 2020 and 2030, driven by the entry of several pipeline agents including IL and JAK inhibitors as well as topical therapies for the treatment of mild to moderate AD. These new entrants will transform the AD market by providing more treatment options for patients across severities and age groups.

Dupixent (dupilumab) will continue to be the market leader with estimated peak sales of $6.2 billion in 2030. It is already known as the gold standard for the treatment of moderate to severe AD across the 7MM

KOLs expressed enthusiasm for the late-stage agents etrasimod, a sphingosine-1-phosphate receptor-1 (S1PR) modulator, and rocatinlimab (KHK4083), an anti-OX40 mAb, due to their new mechanisms of action and the innovation they would bring to the market; if approved they would both be the first in their respective classes.

The most important unmet needs in AD are the lack of therapeutic options for chronic hand eczema (CHE), better long-term disease control and management, as well as more tolerable topical treatment options

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.​

Develop business strategies by understanding the trends shaping and driving the atopic dermatitis (AD) therapeutics market.​

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the seven-market AD market in the future.​

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.​

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.​

Track drug sales in the seven-market AD therapeutics market from 2023-2033.​

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.​

AbbVie
Aclaris Therapeutics
Almirall
Amgen
AOBiome Therapeutics
Apollo Therapeutics
Arcutis Biotherapeutics
Dermavant Sciences
Eli Lilly
Evommune
Galderma
ImageneBio
Incyte
Kymera Therapeutics
Kyowa Kirin
Leo Pharma
Maruho
Nektar Therapeutics
Organon
Otsuka
Pfizer
Regeneron
Sanofi
UCB
Union Therapeutics

Table of Contents

List of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Overview

1.2 68M summary statistics

1.3 Key 7MM events driving the 68M forecast extrapolation

2 Appendix

2.1 Abbreviations

2.2 Methodology

2.2.1 Patient-based forecast methodology

2.2.2 68M forecast extrapolation methodology

2.3 Primary research – key opinion leaders interviewed for this report

2.4 Primary research – prescriber survey

2.5 About the authors

2.5.1 Analyst

2.5.2 Managing analyst

2.5.3 Therapy area directors

2.5.4 Epidemiologist

2.5.5 Epidemiology reviewers

2.5.6 Vice President of Disease Intelligence and Epidemiology

2.5.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence

3 About GlobalData

Contact Us

Table

Table 1: Atopic Dermatitis market size across the 68M – 7MM versus 61M

Table 2: Atopic Dermatitis market size across the 68M – by geographical region

Table 3: Atopic Dermatitis, key events occurring in the 7MM driving forecast trajectory in the 68M

Table 4: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Atopic Dermatitis market size across the 68M – 7MM versus 61M

Figure 2: Atopic Dermatitis market size across the 68M – by geographical region

Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033 in real time.

  • Access a live Atopic Dermatitis: 68-Market Analysis and Drug Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.